Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
BioNTech SE ( (BNTX) ) just unveiled an announcement.
BioNTech reported on March 10, 2026, that its 2025 revenues rose slightly to €2.87 billion, but it swung to a full-year IFRS net loss of €1.14 billion, or €4.70 per diluted share, mainly due to declining COVID-19 vaccine demand and higher operating costs. The company highlighted a strong cash position of €17.2 billion to support a late-stage oncology pipeline, including intensified development of the PD-L11/VEGF-A bispecific pumitamig with Bristol Myers Squibb, and guided 2026 revenues to €2.0–2.3 billion alongside elevated R&D and SG&A spending, while announcing that co-founders Ugur Sahin and Özlem Türeci plan a management transition by end-2026 as they establish an independent next-generation mRNA firm.
Fourth-quarter 2025 revenue fell to €907.4 million from €1.19 billion a year earlier, with quarterly and full-year results pressured by lower COVID-19 vaccine sales and higher other operating expenses linked to settlements, pipeline prioritization and FX effects. Nevertheless, BioNTech said 2025 marked strong execution with multiple programs advancing into late-stage development and expects 2026 to be a catalyst-rich year with six key oncology data readouts that could accelerate its shift away from pandemic-era dependence toward a broader, oncology-led product portfolio.
The most recent analyst rating on (BNTX) stock is a Buy with a $134.00 price target. To see the full list of analyst forecasts on BioNTech SE stock, see the BNTX Stock Forecast page.
Spark’s Take on BNTX Stock
According to Spark, TipRanks’ AI Analyst, BNTX is a Neutral.
BioNTech’s overall stock score reflects a challenging financial performance with recent losses, offset by a strong balance sheet and strategic advancements in oncology. Technical indicators suggest a neutral trend, while valuation remains unattractive due to negative earnings. The earnings call provided positive guidance, but regulatory delays and financial losses remain concerns.
To see Spark’s full report on BNTX stock, click here.
More about BioNTech SE
BioNTech SE is a Germany-based biotechnology company specializing in immunotherapies, notably mRNA-based vaccines and oncology treatments. The company focuses on immuno-oncology, including immunomodulators, antibody-drug conjugates and mRNA cancer immunotherapies, and is working to evolve into a multi-product biopharmaceutical business by 2030.
Average Trading Volume: 939,765
Technical Sentiment Signal: Strong Sell
Current Market Cap: $24.56B
See more insights into BNTX stock on TipRanks’ Stock Analysis page.